Company / EPS (Diluted)
ARDELYX, INC. EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$0.26
FY2025
5-year range
-$1.47 / -$0.17
FY2021-FY2025
Trend
-52.9%
vs FY2024
Sector context
#58 of 204
Health Care
What the data says
At $-0.26, ARDELYX, INC.'s eps (diluted) ranks #58 of 204 in the Health Care sector. EPS (Diluted) has fluctuated over the past 10 years, ranging from $-2.80 in FY2018 to $-0.17 in FY2024.
Based on SEC 10-K filings.
-0.26 in FY2025.
Improved from $-0.30 to $-0.26 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#58 of 204 in Health CareTop 28% of 204This company -$0.26 Sector average -$0.89
▼
+70.7% above sector average
Key checks
Key Insights
- In FY2025, eps (diluted) decreased 52.9% year-over-year.
- Ranks #58 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2024.
- Lowest eps (diluted) in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.41 (distress zone, below 1.8 threshold)
- Negative profit margin: -11.7%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$0.26 | -52.9% |
| FY2024 | -$0.17 | +43.3% |
| FY2023 | -$0.30 | +71.4% |
| FY2022 | -$1.05 | +28.6% |
| FY2021 | -$1.47 | +9.3% |
| FY2020 | -$1.62 | -19.1% |
| FY2019 | -$1.36 | +51.4% |
| FY2018 | -$2.80 | -374.6% |
| FY2017 | -$0.59 | -90.3% |
| FY2016 | -$0.31 | -63.2% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026